Compare LOCO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCO | STTK |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.0M | 275.9M |
| IPO Year | N/A | N/A |
| Metric | LOCO | STTK |
|---|---|---|
| Price | $10.66 | $4.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $14.50 | $6.20 |
| AVG Volume (30 Days) | 220.1K | ★ 658.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | $11.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.29 | $0.69 |
| 52 Week High | $12.65 | $4.89 |
| Indicator | LOCO | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 53.06 |
| Support Level | $10.23 | $3.76 |
| Resistance Level | $10.98 | $4.23 |
| Average True Range (ATR) | 0.30 | 0.32 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 63.93 | 56.38 |
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.